Skip to content
Covid-19
-
Sanofi’s Nuvaxovid exhibits 50% fewer severe side effects than Moderna’s mRNA booster
Less than 10% of participants in the Nuvaxovid group experienced severe side effects that interfered with daily activities compared with 20% in the mNexspike group.
-
BioNTech closes Singapore manufacturing plant as COVID-19 vaccine demand collapses
BioNTech’s decision follows a comprehensive strategic review aimed at aligning the company’s manufacturing capacity with its clinical pipeline and long-term business direction
-
Moderna’s combination Covid-Flu vaccine clears key European regulatory hurdle
The EMA will now proceed with a final decision, potentially clearing the way for global distribution of this combination immunization.